Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Rapport Therapeutics, Inc.’s reported figures.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
FAQ
- What is Rapport Therapeutics, Inc.'s EBITDA?
- Rapport Therapeutics, Inc. (RAPP) reported EBITDA of -$60.59M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s EBITDA changed year-over-year?
- Rapport Therapeutics, Inc.'s EBITDA decreased by 107.2% year-over-year, from -$29.24M to -$60.59M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Rapport Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude